A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Trial Details

NCT ID
NCT06121843
Phase
PHASE1
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • BMS-986393
  • Alnuctamab
  • Mezigdomide
  • Iberdomide
  • Elranatamab
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Duarte, California, United States|34.13945,-117.97729
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1) or at least 1 but not greater than 3 prior anti-myel…
  • Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).
  • Eastern Cooperative Oncology Group performance status of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →